Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets trade flat
Fri, 25 Apr 11:30 am

After opening in the red, the Indian Indices are trading flat in the morning session. The buying interest is highest in metal while the selling pressure is the highest in Energy stocks.

The BSE-Sensex is trading down 20 points and the NSE-Nifty is trading down 12 points. The BSE Mid Cap index is trading up 0.5% and the BSE Small Cap index is trading up 0.6%. The rupee is trading at 61.10 to the US dollar.

If early forecasts are to be believed, India is likely to experience a below normal monsoon this year. As per the Indian Meteorological Department's (IMD) 2014 southwest monsoon forecast, there is only a 35% chance of a normal monsoon this year. The main reason for this is the El Nino, which is a weather phenomenon that heats up the Pacific Ocean and causes droughts in south East Asia as well as in India. The El Nino is expected to hit at the same time as the monsoon season. However it must be emphasized that there is no one to one correlation between the El Nino and the monsoon. If the monsoon were to be adversely affected then it would be bad news for agriculture and allied industries. The agriculture sector had performed well last year as India had received an above normal rainfall.

Indian pharmaceutical stocks are trading mixed today. Strides Arcolabs and Panacea Biotech are leading the gainers. Wockhardt Ltd and Dishman Pharma are leading the losers. According to a leading business daily, Ranbaxy Laboratories will soon be launching first generic version of Swiss drug maker Novartis' Diovan (Valsartan) in the US market. It is a blockbuster blood pressure drug and the company will have 180 days exclusive marketing opportunity for the drug in the US. As per the industry sources, the company may have tied up with Hyderabad-based Divis Labs for the active pharma ingredient (API) formulations. Novartis currently earns around US$ 3.4 bn from this drug globally. Ranbaxy is trading 0.6% down today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets trade flat". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.